Key Highlights

  • Bristol Myers Squibb's $0.63 quarterly dividend has an October 2, 2026 ex-dividend date and is payable November 2 to stockholders of record.
  • Second-quarter revenues were $12,973 million versus $12,269 million, and Growth Portfolio revenues rose 15% to $7.6 billion.
  • GAAP EPS was $1.62 versus $0.64, and non-GAAP EPS was $2.04 versus $1.46 in the second quarter of 2025.
  • The company raised 2026 revenue guidance to ~$49.0 billion to $50.0 billion and non-GAAP EPS guidance to $6.75 to $7.00.

Overview

Bristol Myers Squibb Company's (NYSE:BMY) $0.63 quarterly dividend yields 4.01% and sits beside second-quarter GAAP EPS of $1.62 and non-GAAP EPS of $2.04. The Board declared the dividend on September 16, 2026, the same $0.63 declared in March and June 2026, compared with the $0.62 declared in September 2025.

Dividend Program and Shareholder Returns

The Board declared a quarterly dividend of $0.63 per share on the $0.10 par value common stock on September 16, 2026. It is payable November 2 to stockholders of record at the close of business on October 2.

The March 2, 2026 declaration of $0.63 was payable May 1 to holders of record April 2. The June 17, 2026 declaration of $0.63 was payable August 3 to holders of record July 2. The September 2025 declaration was $0.62, payable November 3, 2025.

About the Company

Bristol Myers Squibb is a biopharmaceutical company headquartered in Princeton, New Jersey, whose stated mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Its Growth Portfolio includes Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag, alongside a Legacy Portfolio of established products.

Financial Performance Behind the Payout

Second-quarter revenues were $12,973 million, up 6% (5% excluding foreign exchange) from $12,269 million. Growth Portfolio revenues were $7.6 billion, up 15%, while Legacy Portfolio revenues were $5,422 million versus $5,624 million. U.S. revenues were $9.0 billion and international revenues were $4.0 billion.

GAAP net earnings attributable to the company were $3,317 million versus $1,310 million. GAAP EPS was $1.62 versus $0.64, and non-GAAP EPS was $2.04 versus $1.46. Non-GAAP net income was $4.2 billion versus $3.0 billion. Gross margin was 71.3% on a GAAP basis and 71.4% on a non-GAAP basis.

A Raised Outlook Built on Growth Portfolio Revenue

The Growth Portfolio's 15% increase to $7.6 billion is the component the company cited when raising its 2026 outlook. Revenue guidance moved to ~$49.0 billion to $50.0 billion from ~$46.0 billion to $47.5 billion. Non-GAAP EPS guidance moved to $6.75 to $7.00 from $6.05 to $6.35.

Operating expense guidance was revised to ~$16.5 billion from ~$16.3 billion.

Outlook

The company's 2026 guidance is revenue of ~$49.0 billion to $50.0 billion and non-GAAP EPS of $6.75 to $7.00. Growth Portfolio revenues, Legacy Portfolio revenues, which declined 4% in the quarter, and operating expenses are the measures reported alongside that guidance.